$SPRCJun 4, 2026, 11:32 AMAI processed
NeuroThera (SciSparc) closes acquisition of ~54% of CliniQuantum for 56.6M shares; up to $2.5M earn-outs
AI Summary
SciSparc's majority‐owned NeuroThera Labs closed the acquisition of approximately 54% of CliniQuantum by issuing 56,600,000 NeuroThera common shares (≈CAD$9.46M based on the 20‐day VWAP) to CliniQuantum shareholders. The deal includes up to US$2.5M in milestone‐based earn‐outs payable in cash and/or shares over three years (tied to patent filings and fundraising), an amendment that sets a CAD$0.05 floor on any earn‐out share issuances, and transfers exclusive rights to a quantum simulation/Monte Carlo clinical‐trial analytics license (currently backed by a single US provisional patent application).
Positives
- NeuroThera obtained a controlling ~54% stake in CliniQuantum, gaining access to quantum simulation/MCMC clinical‑trial analytics IP.
- Consideration consisted of 56,600,000 NeuroThera shares valued at ~CAD$9.46M (20‑day VWAP).
- Earn‑out is capped at US$2.5M and tied to concrete milestones (up to three patent filings and a percentage of fundraising) over a defined three‑year period.
Negatives
- Earn‑outs may be settled in NeuroThera shares, creating potential future dilution (amended floor price CAD$0.05/share).
- The licensed IP is currently a single US provisional patent application, indicating early‑stage and unproven protection.
- A large issuance of NeuroThera shares as deal consideration has already increased share count and may dilute existing equity holders.